Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan
Kazuo Fujihara, Shinya Hirota, Muneyoshi Kudo, Hideaki Hida, Satoshi Yuki, Takashi Narisawa, Kyoko Kato · 2026
Read Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan by Kazuo Fujihara, Shinya Hirota, Muneyoshi Kudo, Hideaki Hida, Satoshi Yuki, Takashi Narisawa, Kyoko Kato (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13615213.txt.
Description
Kazuo Fujihara and co-authors report interim safety and effect data for a relapse prevention drug in a Japanese nerve disease, in work from twenty twenty-six. The disease, NMOSD, attacks the optic nerve and spinal cord in relapses. The drug inebilizumab is approved in Japan for patients with a key antibody.
Nationwide post market tracking covered more than two hundred patients who started the drug from twenty twenty-one to twenty twenty-three. About a third had drug reactions, with infections most common and two deaths that could not be cleared of drug links. Relapse rates fell to a quarter of the prior level after starting. Steroid doses and add on immune drugs dropped sharply by one year. No new safety flags appeared.
Catalog record
| CREATOR | Kazuo Fujihara, Shinya Hirota, Muneyoshi Kudo, Hideaki Hida, Satoshi Yuki, Takashi Narisawa, Kyoko Kato |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |